menu search

MYGN / Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe
Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program. Read More
Posted: Jun 30 2023, 12:57
Author Name: Zacks Investment Research
Views: 110548

MYGN News  

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

By GlobeNewsWire
October 31, 2023

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold more_horizontal

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

By Zacks Investment Research
September 20, 2023

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina. more_horizontal

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

By Zacks Investment Research
September 19, 2023

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer. more_horizontal

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

By Zacks Investment Research
September 12, 2023

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses. more_horizontal

Myriad Genetics: FRα Addition Further Diversifies Portfolio

By Seeking Alpha
September 7, 2023

Myriad Genetics: FRα Addition Further Diversifies Portfolio

Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine t more_horizontal

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

By Zacks Investment Research
August 16, 2023

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test. more_horizontal

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

By Zacks Investment Research
August 11, 2023

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications. more_horizontal

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

By Zacks Investment Research
August 7, 2023

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance. more_horizontal


Search within

Pages Search Results: